AR022250A1 - Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. - Google Patents
Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.Info
- Publication number
- AR022250A1 AR022250A1 ARP000100107A ARP000100107A AR022250A1 AR 022250 A1 AR022250 A1 AR 022250A1 AR P000100107 A ARP000100107 A AR P000100107A AR P000100107 A ARP000100107 A AR P000100107A AR 022250 A1 AR022250 A1 AR 022250A1
- Authority
- AR
- Argentina
- Prior art keywords
- hepatitis
- virus
- treatment
- infections
- patients
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 2
- 208000006454 hepatitis Diseases 0.000 title 2
- 231100000283 hepatitis Toxicity 0.000 title 2
- 208000015181 infectious disease Diseases 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Envase farmacéutico que contiene como ingredientes activos (1) un agente antiviral activo contra el virus de la hepatitis B y (2) una vacuna parala profilaxis y/o tratamiento de la infeccion de la hepatitis B, siendo los ingredientes activosapropiad os para uso simultáneo o secuencial. Los compuestospreferidos son un análogo nucleosídico como agente antiviral, junto con una vacuna para el virus de la hepatitis B, la cual comprende un antígeno de superficiedel virus de la hepatitis B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9900630 | 1999-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022250A1 true AR022250A1 (es) | 2002-09-04 |
Family
ID=10845878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100107A AR022250A1 (es) | 1999-01-12 | 2000-01-11 | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1140163A2 (es) |
| JP (1) | JP2002534438A (es) |
| KR (1) | KR20010090011A (es) |
| CN (1) | CN1391482A (es) |
| AR (1) | AR022250A1 (es) |
| AU (1) | AU760574B2 (es) |
| BR (1) | BR9916893A (es) |
| CA (1) | CA2359110A1 (es) |
| CO (1) | CO5241355A1 (es) |
| CZ (1) | CZ20012544A3 (es) |
| HK (1) | HK1041434A1 (es) |
| HU (1) | HUP0105070A2 (es) |
| IL (1) | IL144186A0 (es) |
| NO (1) | NO20013337L (es) |
| NZ (1) | NZ512890A (es) |
| PL (1) | PL349347A1 (es) |
| TR (1) | TR200102024T2 (es) |
| WO (1) | WO2000041463A2 (es) |
| ZA (1) | ZA200105690B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69932717T2 (de) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
| CN102198266A (zh) | 1998-07-31 | 2011-09-28 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
| BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
| WO2003028758A1 (en) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| WO2003028757A1 (en) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| BR0315810A (pt) | 2002-10-29 | 2005-09-13 | Coley Pharmaceutical Group Ltd | Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| CN100443117C (zh) * | 2003-05-13 | 2008-12-17 | 深圳康泰生物制品股份有限公司 | 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途 |
| US8541167B2 (en) | 2004-06-03 | 2013-09-24 | Saint Louis University | Methods and compositions for vaccination |
| AR065504A1 (es) * | 2007-02-28 | 2009-06-10 | Ct Ingenieria Genetica Biotech | Terapia combinada para el tratamiento de la hepatitis b cronica. uso. |
| EP3903815A4 (en) | 2018-12-24 | 2022-09-28 | Grand Theravac Life Science (Nanjing) Co., Ltd. | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEPATITIS B, METHOD OF MANUFACTURE THEREOF AND USE THEREOF |
| EP4321173A4 (en) * | 2021-04-07 | 2025-08-20 | Denka Company Ltd | ADJUVANT ACTIVITY ACTIVATOR AND ADJUVANT COMPOSITION |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48175A1 (en) * | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
| PL343429A1 (en) * | 1998-03-09 | 2001-08-13 | Smithkline Beecham Biolog | Combined vaccine compositions |
-
1999
- 1999-12-21 BR BR9916893-6A patent/BR9916893A/pt not_active IP Right Cessation
- 1999-12-21 AU AU21009/00A patent/AU760574B2/en not_active Ceased
- 1999-12-21 TR TR2001/02024T patent/TR200102024T2/xx unknown
- 1999-12-21 HK HK02101211.9A patent/HK1041434A1/zh unknown
- 1999-12-21 EP EP99965531A patent/EP1140163A2/en not_active Withdrawn
- 1999-12-21 HU HU0105070A patent/HUP0105070A2/hu unknown
- 1999-12-21 WO PCT/EP1999/010295 patent/WO2000041463A2/en not_active Ceased
- 1999-12-21 KR KR1020017008833A patent/KR20010090011A/ko not_active Withdrawn
- 1999-12-21 PL PL99349347A patent/PL349347A1/xx not_active Application Discontinuation
- 1999-12-21 IL IL14418699A patent/IL144186A0/xx unknown
- 1999-12-21 CZ CZ20012544A patent/CZ20012544A3/cs unknown
- 1999-12-21 JP JP2000593088A patent/JP2002534438A/ja active Pending
- 1999-12-21 NZ NZ512890A patent/NZ512890A/en unknown
- 1999-12-21 CA CA002359110A patent/CA2359110A1/en not_active Abandoned
- 1999-12-21 CN CN99816471A patent/CN1391482A/zh active Pending
-
2000
- 2000-01-11 AR ARP000100107A patent/AR022250A1/es not_active Application Discontinuation
- 2000-01-12 CO CO00001261A patent/CO5241355A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013337A patent/NO20013337L/no not_active Application Discontinuation
- 2001-07-11 ZA ZA200105690A patent/ZA200105690B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010090011A (ko) | 2001-10-17 |
| CO5241355A1 (es) | 2003-01-31 |
| BR9916893A (pt) | 2001-11-20 |
| NO20013337D0 (no) | 2001-07-05 |
| WO2000041463A2 (en) | 2000-07-20 |
| TR200102024T2 (tr) | 2001-12-21 |
| ZA200105690B (en) | 2002-09-25 |
| WO2000041463A3 (en) | 2000-11-09 |
| AU760574B2 (en) | 2003-05-15 |
| HK1041434A1 (zh) | 2002-07-12 |
| JP2002534438A (ja) | 2002-10-15 |
| CA2359110A1 (en) | 2000-07-20 |
| IL144186A0 (en) | 2002-05-23 |
| NZ512890A (en) | 2003-09-26 |
| NO20013337L (no) | 2001-08-17 |
| EP1140163A2 (en) | 2001-10-10 |
| PL349347A1 (en) | 2002-07-15 |
| CN1391482A (zh) | 2003-01-15 |
| CZ20012544A3 (cs) | 2002-01-16 |
| AU2100900A (en) | 2000-08-01 |
| HUP0105070A2 (hu) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| TR199903053T2 (xx) | Benzimidazol t�revleri. | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
| EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
| ES2058892T3 (es) | Uso de omeprazol como agente antimicrobiano. | |
| AR002255A1 (es) | Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion. | |
| AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
| SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
| AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
| AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
| PE20060149A1 (es) | Formulacion farmaceutica para tratar la infeccion por vih | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| AR032151A1 (es) | Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada | |
| BR0108499A (pt) | Agente terapêutico para hepatite c | |
| NO970847L (no) | 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel | |
| AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
| ECSP003859A (es) | Composicion para el tratamiento de tejidos dañados | |
| ES2185310T3 (es) | Agente antivirico herbario. | |
| AR005730A1 (es) | Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato. | |
| CO5160259A1 (es) | Interferon alfa pegilado en la terapia contra el hiv | |
| ES2103811T3 (es) | Terapia antiviral. | |
| AR027037A1 (es) | Compusto y metodo para el tratamiento del dolor | |
| ES2130069B1 (es) | Preparacion farmaceutica con liberacion retardada del producto activo. | |
| CO4790095A1 (es) | Derivados de tienoxacinona inhibodores de la proteasa del herpes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |